An Open-label, Single-center, Randomized, 4-way Crossover Study to Assess the Bioequivalence of R406 in Healthy Volunteers When 100 and 150mg of Fostamatinib Are Administered as the 13% Drug-loaded Tablet Versus the 38% Drug-loaded Tablet
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Fostamatinib (Primary)
- Indications B cell lymphoma; Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms Fosta-BE
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Aug 2012 Actual initiation date (Jul 2012) added as reported by ClinicalTrials.gov.
- 30 Jul 2012 New trial record